Market revenue in 2023 | USD 230.3 million |
Market revenue in 2030 | USD 315.5 million |
Growth rate | 4.6% (CAGR from 2023 to 2030) |
Largest segment | Topical |
Fastest growing segment | Topical |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Oral, Topical |
Key market players worldwide | GSK PLC, Abbott Laboratories, Pfizer Inc, Bausch Health Companies Inc, Bayer AG, Teva Pharmaceutical Industries Ltd, Cipla Ltd DR, Merck & Co Inc, Novartis AG ADR, Sun Pharmaceutical Industries |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to onychomycosis market will help companies and investors design strategic landscapes.
Topical was the largest segment with a revenue share of 57.66% in 2023. Horizon Databook has segmented the Germany onychomycosis market based on oral, topical covering the revenue growth of each sub-segment from 2018 to 2030.
The Germany onychomycosis market is anticipated to be driven by the rising geriatric population. According to the press release issued by the Statistisches Bundesamt (Destatis), a Federal Statistical Office, in December 2022, the number of individuals aged 67 or over in Germany will increase by around 4 million to at least 20.0 million until the middle of the 2030s.
In addition, toenail fungus is very common, especially in the geriatric population. Elderly people are at a higher risk of onychomycosis. Therefore, the demand for medications, drugs, and treatments targeting onychomycosis is expected to significantly increase in Germany owing to the rising geriatric population in the country.
Key market players have undertaken various strategic initiatives to develop drugs and medications for onychomycosis in the country in the past few years. Companies operating in other countries are focusing on increasing access to onychomycosis treatments in Germany.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany onychomycosis market , including forecasts for subscribers. This country databook contains high-level insights into Germany onychomycosis market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account